TOX was only induced in HBV_HCC infiltrating T cells, suggesting that combined anti-PD-1 antibody and TOX-targeting therapy better improve the anti-tumor immune activity of HBV-specific T cells. This evidence concerns the gene PDCD1 and neoplasm.